Relais Q4 adjusted EBITA of EUR 10.8m was up 2% y/y and came 16% below LSEG Data & Analytics consens...
* Sales SEK 18m (+7% vs. ABGSCe 16m) * Better than expected EBIT of SEK -3.
Redeye views BeammWave's Q4 2025 report as a positive read, with the share price likely to respond f...
Stille’s soft share price development over the past months to us appears more sentiment-driven than ...
CEO Joakim Nydemark discusses the year-end report and the events of the past year, business model, o...
Redeye updates on Better Collective ahead of Q4-results (due 25 February after market close) where w...
Atria's Q4 adjusted EBIT came in slightly below LSEG Data & Analytics consensus, driven by ASF- rela...
Q4 net sales and adjusted EBITDA were relatively close to our expectations, but several one-off-rela...
Redeye provides an update following Neola Medical’s Q4 2025 report.
Tradedoubler's Q4 report showcased solid underlying execution in a cautious market environment.
Redeye keeps its positive view of Vertiseit following a decent Q4 report.
Redeye retains its positive view of CombinedX following a solid Q4, with strong underlying margins.
In Q4, CapMan performed in the areas that matter. The company raised around EUR 340m during the quar...
* Q4 report Tuesday, 17 February at 08:30 CET * '25e-'27e adj.
Q4 adjusted EBITDA was in line with our estimate, but adjustments burdened net results.
Railcare avslutade året med ett kvartal där svaghet inom Entreprenad vägdes upp av en förbättring in...
Redeye comments on Invisio’s Q4-results which easily beat our forecasts while order intake was also ...
* NOI 2% y-o-y, 2.4% vs ABGSCe, 1.5% vs cons. * Value changes of -0.
CEO Joachim Samuelsson discusses the year-end report and the events of the past year, business model...
Redeye comments on Hansa Biopharma's Q4 report. Revenues were SEK76m in the quarter, a strong beat o...
